Craig Woods DVM, MS, MBA, general manager for BioVeteria stated, "We are very excited to be working with CAN on this new technology. The technology represents a significant advancement in veterinary orthopedics and proposes to improve our understanding on new techniques for cartilage and bone regeneration. In addition, our comparative work in dogs and horses will benefit our understanding for human medicine."
Johnathan Riley, Managing Director of the Canadian Arthritis Network, says "CAN is very pleased to be working with BioVeteria to bring Dr. Anastassiades' ANABUTM technology to market. Dr. Anastassiades has performed extensive research that has demonstrated striking benefits of ANABUTM in arthritis and osteoporosis animal models."
The technology was discovered and developed by Tassos Anastassiades, MD, PhD, a leading expert in glucosamine derivatives in arthritis and bone-related diseases. The technology is an optimized glucosamine derivative, having shown significantly better effects on cartilage and bone systems when compared to glucosamine. The lead compound has been extensively evaluated in vitro and in vivo, and is the subject of publications in the Journal of Rheumatology and Journal of Pharmacology and Experimental Therapeutics.
About Dr. Tassos Anastassiades: Dr. Anastassiades is Professor of Medicine and Biochemistry and Head of the Division of Rheumatology at Queen's University in Kingston, Ontario, Canada. Dr. Anastassiades has been involved in characterizing glucosamine derivatives for their effects on bone and cartilage and is the inventor of patents related to the technology.
About BioVeteria Life Sciences, LLC: BioVeteria is a biopharmaceutical company located in Prescott, AZ, which is developing F(ab')2 snake antivenom, diagnostics and therapeutic products for high demand indications including veterinary orthopedics, critical care, and ophthalmology. For more information, visit www.BioVeteria.com.
About the Canadian Arthritis Network: The Canadian Arthritis Network is one of Canada's a federally funded National Centres of Excellence and is a single point of contact for more than 200 leading Canadian arthritis researchers and clinician scientists. CAN works in close collaboration with its Consumer Advisory Council, comprised of people living with arthritis, to develop R&D programs that make a difference, including R&D programs that facilitate technology transfer and commercialization of new discoveries. For more information, visit www.arthritisnetwork.ca.
Contact Information:
Craig Woods
info@BioVeteria.com
928.776.1813
Stacey Johnson - Dir. of Communication
Canadian Arthritis Network
sjohnson@mtsinai.on.ca
416.586.4685
